Insulet Co. (NASDAQ:PODD) COO Charles Alpuche sold 7,090 shares of the company’s stock in a transaction dated Thursday, March 15th. The stock was sold at an average price of $84.65, for a total transaction of $600,168.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Shares of PODD opened at $83.77 on Friday. The stock has a market capitalization of $4,891.41, a P/E ratio of -182.11 and a beta of 1.38. The company has a debt-to-equity ratio of 3.57, a current ratio of 6.24 and a quick ratio of 5.85. Insulet Co. has a 52-week low of $38.43 and a 52-week high of $88.88.
Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04). Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. The company had revenue of $130.50 million during the quarter, compared to the consensus estimate of $125.16 million. During the same quarter in the prior year, the company earned ($0.16) EPS. The business’s quarterly revenue was up 26.0% on a year-over-year basis. equities research analysts expect that Insulet Co. will post -0.29 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Cerebellum GP LLC acquired a new stake in Insulet in the 4th quarter valued at about $122,000. Equitec Specialists LLC acquired a new stake in Insulet in the 4th quarter valued at about $145,000. James Hambro & Partners acquired a new stake in Insulet in the 4th quarter valued at about $165,000. C M Bidwell & Associates Ltd. acquired a new stake in Insulet in the 4th quarter valued at about $188,000. Finally, Diversified Trust Co acquired a new stake in Insulet in the 4th quarter valued at about $218,000.
Several equities analysts have recently commented on PODD shares. Barclays restated a “buy” rating and set a $78.00 price target on shares of Insulet in a research report on Wednesday, December 13th. BidaskClub upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 23rd. Guggenheim started coverage on shares of Insulet in a research report on Tuesday, April 3rd. They set a “buy” rating and a $105.00 price target for the company. Zacks Investment Research lowered shares of Insulet from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, Oppenheimer set a $82.00 price target on shares of Insulet and gave the stock a “hold” rating in a research report on Thursday, February 22nd. Seven investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Insulet presently has a consensus rating of “Buy” and a consensus price target of $75.00.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/08/insider-selling-insulet-co-podd-coo-sells-7090-shares-of-stock.html.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.